Geulah Livshits
Stock Analyst at Chardan Capital
(4.30)
# 388
Out of 5,112 analysts
245
Total ratings
47.97%
Success rate
18.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $8.69 | +199.19% | 14 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $110 → $174 | $96.24 | +80.80% | 6 | Dec 16, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 → $8 | $0.67 | +1,097.60% | 14 | Dec 12, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $9.96 | +70.68% | 13 | Dec 11, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 → $13 | $1.17 | +1,011.11% | 11 | Dec 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $74 | $54.84 | +34.94% | 16 | Nov 26, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $9.57 | +161.23% | 3 | Nov 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $20 | $5.67 | +252.73% | 15 | Nov 13, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 → $21 | $9.44 | +122.46% | 6 | Nov 12, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $10 → $9 | $3.60 | +150.00% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $26 | $8.88 | +192.79% | 17 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $2.46 | +591.06% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $5.45 | +120.18% | 16 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $5.28 | +184.09% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $220 | $233.37 | -5.73% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $3.23 | +240.56% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.66 | +562.65% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.76 | +685.96% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.35 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.96 | +415.08% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.41 | +397.93% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $30.95 | +572.05% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.88 | +1,725.86% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $13.51 | +566.17% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $4.12 | -2.91% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $19.95 | -9.77% | 1 | Oct 27, 2020 |
4D Molecular Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $26
Current: $8.69
Upside: +199.19%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $110 → $174
Current: $96.24
Upside: +80.80%
Tenaya Therapeutics
Dec 12, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $0.67
Upside: +1,097.60%
Lexeo Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $17
Current: $9.96
Upside: +70.68%
Senti Biosciences
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $1.17
Upside: +1,011.11%
CRISPR Therapeutics AG
Nov 26, 2025
Maintains: Buy
Price Target: $82 → $74
Current: $54.84
Upside: +34.94%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $9.57
Upside: +161.23%
Immuneering
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.67
Upside: +252.73%
Passage Bio
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $9.44
Upside: +122.46%
Prime Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.60
Upside: +150.00%
Nov 7, 2025
Maintains: Buy
Price Target: $48 → $26
Current: $8.88
Upside: +192.79%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $2.46
Upside: +591.06%
Nov 5, 2025
Maintains: Buy
Price Target: $12
Current: $5.45
Upside: +120.18%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $5.28
Upside: +184.09%
Nov 4, 2025
Maintains: Buy
Price Target: $216 → $220
Current: $233.37
Upside: -5.73%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.23
Upside: +240.56%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.66
Upside: +562.65%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.76
Upside: +685.96%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.35
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.96
Upside: +415.08%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.41
Upside: +397.93%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $30.95
Upside: +572.05%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.88
Upside: +1,725.86%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $13.51
Upside: +566.17%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $4.12
Upside: -2.91%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $19.95
Upside: -9.77%